BMJ Open

SENOVIE, France | Medical Questionnaire

Please complete the questionnaire below.

Thank you!

IDENTIFICATION	
Q001. Name of Inclusion Hospital	Saint-Louis Delafontaine Robert Ballanger Avicenne
Q002. Date of inclusion of the woman	
Q003. Participant ID	
	(Double entry of the SENOVIE identifier)
Q004. Year of birth of the participant	

Q005. Country of birth of the participant	○ Other
	○ country
	○ France
	O South Africa
	○ Angola
	Benin
	O Botswana
	O Burkina Faso
	Burundi
	Cameroon
	Cape Verde
	O Comoros
	○ Côte d'Ivoire
	O Djibouti
	O Eritrea
	© Ethiopia
	Gabon
	Gambia
	○ Gambia ○ Ghana
	Glialia O Guinea
	Guinea Guinea-Bissau
	C Equatorial Guinea
	○ Kenya
	C Lesotho
	Liberia
	○ Madagascar
	O Malawi
	C Little
	Mauritania
	Mozambique
	Namibia
	O Niger
	O Nigeria
	Uganda
	Central African Republic Democratic
	Republic of the Congo
	Rwanda
	São Tomé and Principe
	Senegal ·
	Seychelles,
	◯ Sierra Leone,
	🔾 Somalia,
	South Sudan,
	Swaziland,
	🔾 Tanzania,
	Chad
	○ Togo
	Zambie
	Zimbabwe
Q005.1 Other country of birth, specify	
action country or birting specify	
Q006. Date of First Diagnostic Biopsy	
2 2	
Q006.1 Biopsy site (country)	
	(Note the country of ID-16 lives III of the country of III
	(Note the country or "Don't know" if you don't have the information)

Q007. Date of first documented consultation in the medical file for the management of the cancer?	
Q009. Family history of breast cancer / ovary ?	○ No ○ Yes
Q010. Circumstances of breast cancer diagnosis	Clinical signScreening (during a campaign or individual screening)
Q011. HIV Positive	○ No ○ Yes
Q011.1. Date of HIV diagnosis	
CLINICAL	
Q012.1 Size in cm	
	(Note only the numeric values. For 1m65, rate 165)
Q012.2 Weight in Kg (first known)	
	(Note only the numeric values. For 65 kg, rate 65)
Q013. Menopausal at the time of diagnosis	○ No ○ Yes
Q014. Pregnancy in progress at the time of diagnosis	○ No ○ Yes
Q015. Clinical tumour size (cT)	 □ T0 □ T1 □ T2 □ T3 □ T4 (Information to be collected in the medical file)
Q016. Clinical Classification of Lymph Nodes (cN)	 N0 N1 N2 N3 (Information to be collected in the medical file)
Q017. Clinical presence of distant metastasis (clinical or radiological metastasis)	○ M0 ○ M1

PATHOLOGICAL	
Q018. Form of cancer	○ In situ○ Infiltrating
Q019. Histological type	NST (Invasive Canal)Infiltrating lobularOther
Q019.1. Other histological type, please	
specify	(Note the type or "Don't know" if you don't have the information)
Q020. Grade SBR	○ 1 ○ 2 ○ 3
Q021. Emboles	○ No ○ Yes
Q022.1 ER (estrogen receptors)	Negat ive Positiv e
Q022.2 PR (progesterone receptors)	O Negat ive Positiv e
Q022.3 HER 2	Negative (0, 1+, 2+ unamplified)Positive (2+ amplified, 3+)
Q023.1 pTNM or ypTNM ?	○ pTNM ○ ypTNM (neo-adjuvant)
Q023.2 Tumour size (pT or ypT)	 ○ T0 ○ Tis ○ T1 ○ T2 ○ T3 ○ T4 (Information to be collected in the medical file)
Q024. Classification of the lymph nodes (pN or ypN)	 N0 N1 N2 N3 (Information to be collected in the medical file)
Q025. Presence of distant metastasis (pM or ypM)	○ M0 ○ M1

Q026. Stage of cancer at diagnosis?	○ 0 ○ I
	O IIA
	○ IIB ○ IIIA
	○ IIIB
	Ŏ IIIC
	O IV
	(Information to be collected in the medical file)
Q027. Has she had chemotherapy in treatment?	○ No
initial (regardless of the location)?	○ Yes
Q027.1 Type of chemotherapy	Adjuvant Neo-
	adjuvantNeo-adjuvant + metastatic adjuvant
	Neo-adjuvant + metastatic adjuvant
Q027.2 Chemotherapy start date	
Q027.3 Chemotherapy end date	
O027 4 Type (therapoutic class)	
Q027.4 Type (therapeutic class)	
	(Note the type or "Don't know" if you don't have the information)
Q027.5 Number of Chemotherapy Cycles	
	(Write down the exact number or "999" if you don't have the information)
Q027.6 Has she received all or part of her	○ No
chemotherapy outside France?	○ Yes
Q027.6.1 In which	
country?	(Note the country or "Don't know" if you don't have the
	information)
Q028. Did she have surgery as an initial treatment?	○ No
(regardless of the location)?	○ Yes
Q028.1. Date of First Surgery	
Q028.2. What type of surgery?	☐ Total mastectomy☐ Partial mastectomy
	Axillary dissection
	☐ Sentinel lymph node
	Other
	(Several answers possible)
Q028.2.1. Other types of surgery, please specify	

Q028.3. Side of surgery	○ Right○ Left○ Bilateral
Q028.4. Revision surgery	○ No ○ Yes
Q028.5 Has she received all or part of her surgery outside France?	○ No ○ Yes
Q028.5.1 In which country?	(Note the country or "Don't know" if you don't have the information)
Q028.6. Did she have reconstructive surgery (regardless of the location)?	○ No ○ Yes
Q028.6.1. Has it received all or part of its reconstructive surgery outside France?	○ No ○ Yes
Q028.6.1.1. In which country?	(Note the country or "Don't know" if you don't have the information)
Q029. Has she had radiation therapy in treatment? initial (regardless of the location)?	○ No ○ Yes
Q029.1. Radiation therapy start date	
Q029.2. End date of radiation therapy	
Q029.3. Which areas were irradiated?	□ Breast□ chest wall Lymph□ node areas Other□ areas
Q029.3.1. Other irradiated areas, specify which ones	
Q029.4. Has she received all or part of her radiotherapy outside France?	○ No ○ Yes
Q029.4.1. In which country?	(Note the country or "Don't know" if you don't have the information)
Q030. Has she had hormone therapy in treatment? initial (regardless of the location)?	○ No ○ Yes
Q030.1. Hormonal Therapy Start Date	

Q030.2. End date of hormonal therapy	
Q030.3. What treatments did the patient receive for his hormone therapy (regardless of the location)?	 ⊤amoxifen Anti-aromatase LH-RH Agonist Others
Q030.3.1. Other treatments received with hormone therapy, please specify	
Q030.4. Has it received all or part of its Hormone therapy outside France?	○ No ○ Yes
Q030.4.1. In which country?	
Q031. Has she had targeted therapy in treatment? initial (regardless of the location)?	○ No ○ Yes
Q031.1. What targeted therapies did she receive?	Trastuzumab (Herceptin)Immunotherapy (Pembrolizumab)Other
Q031.2. Other targeted therapies received, please specify	
Q031.4 Has she received all or part of her therapy targeted outside France?	○ No ○ Yes
Q031.4.1. In which country?	(Note the country or "Don't know" if you don't have the information)
Q033. Has she had a local recurrence (regardless of the moment, whatever the country)?	○ No ○ Yes
Q033.1. Date of the first documented local recurrence	
Q034. Has she had a metastatic recurrence (what whatever the time, whatever the country)?	○ No ○ Yes
Q034.1. Date of First Documented Metastatic Recurrence	·
Q034.2. Treatments received since metastatic recurrence	☐ Chemotherapy ☐ Intravenous Targeted ☐ Therapy Hormone Therapy ☐ Oral Targeted ☐ Therapy ☐ Radiotherapy ☐ Surgery Other

Q034.2.1. Other treatments received since metastatic recurrence, please specify		
	(Note the treatment or "Don't know" if you don't have the information)	
Q034.3. Number of lines of treatment received since metastatic recurrence		
	(Write down the exact number or "999" if you don't have the information)	
Q034.5. Has he received all or part of the treatments for metastatic recurrence outside France ?	○ No ○ Yes	
Q034.5.1 In which country?		
country:	(Note the country or "Don't know" if you don't have the information)	
Q036. Has she received an offer to meet A palliative care team?	○ No ○ Yes	
Q036.1. Did she meet with a health care team? Palliative?	○ No ○ Yes	
Q037. What treatments was the patient receiving at the time of the investigation?	☐ Chemotherapy ☐ Intravenous Targeted	
the time of the investigations	☐ Therapy Hormone Therapy	
	☐ Oral Targeted	
	☐ Therapy ☐ Radiotherapy	
	☐ Surgery Other	
Q037.1. Other treatments received at the time		
of the survey, please specify	(Note the treatment or "Don't know" if you don't have the information)	
Q038 Participant ID		
	(Double entry of the SENOVIE identifier)	